Halestrap Andrew P, Clarke Samantha J, Khaliulin Igor
Department of Biochemistry and Bristol Heart Institute, University of Bristol, School of Medical Sciences, University Walk, Bristol BS8 1TD, UK.
Biochim Biophys Acta. 2007 Aug;1767(8):1007-31. doi: 10.1016/j.bbabio.2007.05.008. Epub 2007 Jun 2.
A prolonged period of ischaemia followed by reperfusion irreversibly damages the heart. Such reperfusion injury (RI) involves opening of the mitochondrial permeability transition pore (MPTP) under the conditions of calcium overload and oxidative stress that accompany reperfusion. Protection from MPTP opening and hence RI can be mediated by ischaemic preconditioning (IP) where the prolonged ischaemic period is preceded by one or more brief (2-5 min) cycles of ischaemia and reperfusion. Following a brief overview of the molecular characterisation and regulation of the MPTP, the proposed mechanisms by which IP reduces pore opening are reviewed including the potential roles for reactive oxygen species (ROS), protein kinase cascades, and mitochondrial potassium channels. It is proposed that IP-mediated inhibition of MPTP opening at reperfusion does not involve direct phosphorylation of mitochondrial proteins, but rather reflects diminished oxidative stress during prolonged ischaemia and reperfusion. This causes less oxidation of critical thiol groups on the MPTP that are known to sensitise pore opening to calcium. The mechanisms by which ROS levels are decreased in the IP hearts during prolonged ischaemia and reperfusion are not known, but appear to require activation of protein kinase Cepsilon, either by receptor-mediated events or through transient increases in ROS during the IP protocol. Other signalling pathways may show cross-talk with this primary mechanism, but we suggest that a role for mitochondrial potassium channels is unlikely. The evidence for their activity in isolated mitochondria and cardiac myocytes is reviewed and the lack of specificity of the pharmacological agents used to implicate them in IP is noted. Some K(+) channel openers uncouple mitochondria and others inhibit respiratory chain complexes, and their ability to produce ROS and precondition hearts is mimicked by bona fide uncouplers and respiratory chain inhibitors. IP may also provide continuing protection during reperfusion by preventing a cascade of MPTP-induced ROS production followed by further MPTP opening. This phase of protection may involve survival kinase pathways such as Akt and glycogen synthase kinase 3 (GSK3) either increasing ROS removal or reducing mitochondrial ROS production.
长时间缺血后再灌注会对心脏造成不可逆损伤。这种再灌注损伤(RI)涉及在再灌注时伴随的钙超载和氧化应激条件下线粒体通透性转换孔(MPTP)的开放。缺血预处理(IP)可介导对MPTP开放及由此导致的RI的保护作用,即在长时间缺血期之前先进行一个或多个短暂(2 - 5分钟)的缺血和再灌注循环。在简要概述MPTP的分子特征和调节之后,本文回顾了IP减少孔开放的可能机制,包括活性氧(ROS)、蛋白激酶级联反应和线粒体钾通道的潜在作用。有人提出,IP介导的再灌注时对MPTP开放的抑制并不涉及线粒体蛋白的直接磷酸化,而是反映了长时间缺血和再灌注期间氧化应激的减轻。这导致MPTP上关键巯基的氧化减少,已知这些巯基会使孔开放对钙敏感。在长时间缺血和再灌注期间IP心脏中ROS水平降低的机制尚不清楚,但似乎需要通过受体介导的事件或IP方案期间ROS的短暂增加来激活蛋白激酶Cε。其他信号通路可能与这一主要机制相互作用,但我们认为线粒体钾通道不太可能起作用。本文回顾了它们在分离的线粒体和心肌细胞中的活性证据,并指出用于表明它们在IP中起作用的药理剂缺乏特异性。一些钾通道开放剂会使线粒体解偶联,而其他一些则抑制呼吸链复合物,真正的解偶联剂和呼吸链抑制剂可模拟它们产生活性氧和预处理心脏的能力。IP还可能通过防止MPTP诱导的活性氧产生级联反应以及随后进一步的MPTP开放,在再灌注期间提供持续保护。这种保护阶段可能涉及存活激酶途径,如Akt和糖原合酶激酶3(GSK3),它们要么增加活性氧的清除,要么减少线粒体活性氧的产生。